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Abstract
Background: Renal transplant recipients are at high risk of developing multiple infections, often concomitantly
because of their immunocompromised status. Post renal transplant infections are often elusive and require
extensive evaluation for proper diagnosis and treatment. A high index of suspicion is required and an attempt
should be made to confirm the microbiological diagnosis from each site involved to rule out multiple infections.
Case presentation: We report a 50-year-old female, a renal allograft recipient who presented with left hemiplegia,
esophageal ulcers and fever 3 months after her transplant. Esophageal biopsy revealed Cytomegalovirus (CMV)
inclusions and the whole blood quantitative CMV polymerase chain reaction (PCR) was positive. Neuroimaging
showed a brain abscess, stereotactic biopsy from which revealed Scedosporium apiospermum on fungal culture. Her
tacrolimus and mycophenolate were stopped and she was managed with intravenous ganciclovir and voriconazole.
With these measures, she showed marked improvement in her general and neurological condition. Two months
later, she developed recurrence of fever with dry cough. Radiological investigation revealed a cavitating lung lesion,
a needle aspiration from which demonstrated acid-fast bacilli. She was started on antituberculous treatment. With
these measures, she recovered completely and maintained good graft function despite being on only prednisolone
10 mg once a day.
Conclusion: Although CMV disease is not uncommon in the first three months post transplant, Scedosporium is a
rare cause of brain abscess. On the other hand, tuberculosis is common in transplant recipients, especially in
developing countries, like India. However, this is the first case report of occurrence of these three infections in the
same patient, demonstrating the importance of a good microbiological work-up from each site involved in
immunosuppressed subjects.
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Background
Renal transplantation is the best option for patients
with end-stage kidney disease, more so for those in de-
veloping countries where facilities for maintenance dia-
lysis are inadequate [1]. Although survival rates after
renal transplantation have improved considerably, in-
fections remain a major cause of morbidity and mortal-
ity in countries with poor socioeconomic conditions.
Studies from such countries have reported infection rates
in the range of 50-80% and a mortality rate of 20-60%,
particularly with severe opportunistic and fungal infec-
tions [2,3]. Various bacterial, viral, fungal and mycobac-
terial infections may occur simultaneously or sequentially
and tissue sampling is often the only mode of conclusive
diagnosis. Cytomegalovirus (CMV) and mycobacterial in-
fections are common and well described post renal trans-
plant infections, particularly in the period of intense
immunosuppression; however, Scedosporium is a rare
fungal pathogen affecting renal transplant recipients. We
report a rare case of CMV, Scedosporium apiospermum,
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and Mycobacterium tuberculosis infection in a renal trans-
plant recipient, all of which were managed successfully.
Case presentation
A 50-year-old housewife was diagnosed to have end-
stage renal disease of uncertain etiology. After being on
hemodialysis for one year, she underwent living unrelated
renal transplantation at another centre with basiliximab
induction followed by triple drug immunosuppression
with tacrolimus (trough level 6.7-8.8 ng/mL), mycophe-
nolate mofetil (1 gm twice daily) and prednisolone (5 mg
daily). The pretransplant CMV sero-status of the donor
and recipient was not known and she was not on prophy-
laxis for CMV. Three months post transplant, she was
admitted with fever, headache, oral ulcers and dysphagia
of one week duration and soon after admission she devel-
oped slurring of speech with drowsiness and weakness of
left upper and lower limbs. During the preceding three
months, she had maintained normal graft function and
did not receive any anti-rejection therapy. There was no
history of contact with pets or occupational exposure. At
presentation, she was hemodynamically stable, febrile,
had multiple oral ulcers with left hemiparesis and right
upper motor neuron facial palsy. Her hemoglobin was
112 gm/L, total leukocyte count 7.8 × 109/L, platelet
count 145 × 109/L and serum creatinine 78 μmol/L. Non-
contrast computerized tomography (CT) followed by
magnetic resonance imaging of brain revealed a 3 × 3 cm
hypodense lesion in right temporo-parietal region with
significant peri-lesional edema (Figure 1A & B). An endo-
scopic examination for dysphagia revealed multiple
esophageal ulcers, biopsy from which was positive for
cytomegalovirus inclusions. Whole blood quantitative
polymerase chain reaction (PCR) for CMV was positive
with 17500 copies/mL. Simultaneously, a stereotactic bi-
opsy from the brain lesion was performed. Fungal stain-
ing of the material showed septate hyphae, while fungal
cultures grew melanin producing filamentous fungi with
brown-black colonies. A lactophenol cotton blue mount
demonstrated numerous single-celled, broadly clavate to
ovoid conidia, 4–9 × 6–10 mm in size, rounded above
with truncate bases, borne singly or in small groups on
elongated, simple or branched conidiophores or on hy-
phae. These features confirmed the diagnosis of Scedos-
porium apiospermum (Figure 2). Mycophenolate mofetil
and tacrolimus were stopped and she was started on
intravenous (i.v.) ganciclovir and i.v. voriconazole. After
one week of therapy, she became afebrile with improve-
ment of power in the left upper limb. A repeat CT scan of
the head done after one week showed reduction in size of
the lesion (Figure 1C). After 3 weeks of therapy, the pa-
tient showed significant improvement in the slurred
speech and she became ambulatory with support. There
was significant reduction in size in repeat CT scan. Repeat
CMV PCR done after three weeks was negative and pa-
tient was started on valganciclovir prophylaxis and oral
voriconazole. The levels of voriconazole were monitored
and maintained between 1–5.0 μg/mL for initial 3 months.
At the end of two months, she was readmitted with fever
and dry cough. Chest radiograph and high resolution CT
chest showed thin smooth walled cavitary lesion with sur-
rounding consolidation. A fine-needle aspiration demon-
strated acid-fast bacilli, which were confirmed to be
Mycobacterium tuberculosis on culture. A CT chest was
not obtained during the first hospitalization, thus we can-
not exclude the possibility of either Scedosporium or tu-
berculosis in the lung at that time. She responded well
with rifampicin based four drug antituberculous therapy.
During the first month of rifampicin therapy, the median
dose of voriconazole needed to be increased to 600 mg
per day to maintain its levels in the therapeutic range,
while subsequently voriconazole was given at a fixed dose
of 200 mg once a day as secondary chemoprophylaxis. At
six months of follow-up, she had recovered completely.
She was maintaining normal graft function with prednisol-
one 10 mg once a day with a plan to introduce azathio-
prine. She continues to take 200 mg of voriconazole, while
her antituberculous therapy and valganciclovir have been
stopped. She was evaluated for an occult primary im-
munosuppressive disorder with defective cell mediated
Figure 1 Radiology of head. (A) NCCT head showing a large hyperdense lesion in the right temporo-parietal region with peri-lesional edema,
which is confirmed on MRI (B). Significant reduction in size of the lesion after drainage and antifungal therapy on repeat NCCT head (C).
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immunity, in view of the repeated life threatening infec-
tions. There was no hypogammaglobulinemia or CD4 cy-
topenia and her human immunodeficiency virus (HIV)
status was negative.
Discussion
The risk of infections in transplant recipients is determined
by the intensity of epidemiologic exposure to potential
pathogens and the net state of immunosuppression. The
reasons for higher rates of infection in developing coun-
tries include factors like unhygienic conditions, hot and
humid environment, overcrowding, high prevalence of en-
demic infections like tuberculosis, malnutrition, late pres-
entation, unavailability of costly diagnostic investigations
like polymerase chain reaction and high cost of life saving
antimicrobials [2,3].
CMV is the most frequent pathogen encountered in
renal transplant recipients in countries with a temperate
climate. CMV infection usually occurs during the second
to fourth month period after transplantation; however,
delayed onset can be seen in patients on chemoprophy-
laxis [4,5]. The infection can either be asymptomatic or
cause illness of varying severity, depending upon the
serological status of the recipient and the donor. In our
case, the renal transplant was done at another centre and
therefore the pretransplant CMV sero-status of the donor
and recipient was not known and she also did not receive
CMV chemoprophylaxis. CMV is a potentially prevent-
able disease with the use of prophylactic therapy, espe-
cially in high-risk cases, those who receive an induction
therapy and who require potent anti-rejection therapy [6]
and we feel that the present case would have benefitted
by the use of chemoprophylaxis.
Brain abscess is an uncommon infectious complication
in renal transplant recipients. Selby et al. [7] described
disparate groups of patients with brain abscesses with re-
gard to the timing, susceptibility and predisposition. He
found that while fungi (ie, Aspergillus, Candida, and
Mucorales sp) contributed to most of the early onset
brain abscesses (median 24 days); abscesses that devel-
oped late after transplantation (mean 264 days) were
caused by non fungal organisms (i.e., Nocardia and Toxo-
plasma sp). In another report, Aspergillus species were
the most commonly isolated organism [8].
Scedosporium apiospermum is the anamorph of the
ascomycete Pseudallescheria boydii which is a genus of
the Ascomycete order Microascales. Scedosporium infec-
tions account for about 3% of all fungal infections in
post transplant patients with 70% mortality [9]. Scedos-
porium usually causes cutaneous infection; however,
sometimes it can cause a disseminated infection [10-12],
although isolated brain infection is rare. Being com-
monly found in heavily polluted environments, agricul-
tural and garden soil, sewer, ditch mud and polluted
pond bottoms, drowning is a common cause for brain
infection with this fungus [13]. It is commonly misdiag-
nosed as Aspergillus due to its septate hyphal morph-
ology. A search of Pubmed and EMBASE has revealed
about eight cases of post renal transplant brain scedos-
poriosis [11,12,14-19].
Our case did not have any known exposure to above
mentioned environmental factors nor had past history of
Figure 2 Mycological work-up of brain abscess aspirate. (A) KOH (potassium hydroxide) mount showing thin septate hyphae in the pus from
brain abscess, (B) Lactophenol cotton blue mount of culture material showing numerous single-celled, broadly clavate to ovoid conidia, 4–9 x 6–10 mm,
rounded above with truncate bases, borne singly or in small groups on elongate, simple or branched conidiophores or laterally on hyphae (C).
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any other fungal infection. She was managed successfully
with voriconazole therapy. Voriconazole produces a
quick and sustained response with cure rates of up to
57% in immunocompromised subjects with those having
brain infection being the worst responders [20]. The in-
fection may persist in the body for long periods of time
and has been reported to recur after a second transplant
[17,21] and therefore it might be appropriate to give
prolonged secondary chemoprophylaxis.
The incidence of post transplant tuberculosis varies
from 0.48% in the west [22] to 11.8% in India [23]. Thera-
peutic response is often satisfactory and drug interactions
mandate dose adjustment of other immunosuppression
drugs as well as azoles. British thoracic society and Euro-
pean Best Practice Guidelines recommend rifampicin-
based four drug therapy for 6 months with blood level
monitoring for calcineurin inhibitors [24,25]. Similarly, if
the patient is on azoles, the drug levels should be moni-
tored. Although pretransplant evaluation and treatment
for latent tuberculosis is recommended, in highly en-
demic countries like ours, both of these strategies are
faced with problems. Due to high endemicity and an in-
creased chance of exposure, evaluation for latent tuber-
culosis has been shown to be nonspecific and insensitive
[26]. Similarly, the treatment of latent tuberculosis by
using isoniazid monotheraphy is prone for the develop-
ment of resistant tuberculosis [27] and there is no con-
sensus on whether latent tuberculosis should be treated
in countries otherwise endemic for this infection [28].
Conclusion
Opportunistic infections in post transplant subjects are
very common and require high index of suspicion and
proper investigative approach for early diagnosis and
treatment. Co-infections can be a diagnostic problem as
one infection can easily undermine the existence of the
other. In the presence of CMV infection, a co-existent
fungal infection needs careful exclusion. Pharmacody-
namic monitoring with maintenance of therapeutic levels
of immunosuppressive drugs within the prescribed range
and tailoring of immunosuppression as per the immuno-
logical risk of the patient may provide the long sought
balance of adequate immunosuppression with minimal
opportunistic infections and malignancies.
Our case appears to be the first in the literature with
the triad of CMV, Scedosporium apiospermum and Myco-
bacterium tuberculosis infection, all of which were man-
aged successfully. In the present case, since a CT of the
chest was not done during the first admission, the prob-
ability of pulmonary tuberculosis being there at that time
itself cannot be ruled out, though it manifested two
months later. This case highlights the importance of get-
ting a microbiological diagnosis from each site involved.
One should not assume that if one organism has been
isolated, the other manifestations are also because of the
same organism. This case also exemplifies the need for
tailored immunosuppression for renal transplant recipi-
ents to reduce their susceptibility to infections.
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